Lexicon Pharmaceuticals partnered with Novo Nordisk on asset LX9851 for optionality.
2 reports, 2 independent
Updated Aug 1
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lexicon Pharmaceuticals partnered with Novo Nordisk on asset LX9851 for optionality.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Licensing agreement provides prior-year revenue for the partnership between Lexicon and Novo Nordisk.1 source
Lexicon Pharmaceuticals partnered with Novo Nordisk regarding asset LX9851.1 source
Keep exploring
The entities involved
-
Lexicon Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
Novo Nordisk
Danish pharmaceutical company